• Tech
• Gadgets
• Mobile
• Enterprise
• CrunchBase
• More
  • Beta Invites
  • Elevator Pitches
  • Gillmor Gang
  • Podcasts
  • TechCrunch50
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

GlycoMimetics

edit

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

Milestones

edit

• 
  GlycoMimetics received $38M in Unattributed funding. (10/09)
  Posted 10/21/09 at 11:56pm
• 
  GlycoMimetics added Rachel K. King as Founder, CEO.
  Posted 10/21/09 at 11:56pm
• 
  GlycoMimetics added John Magnani as Chief Scientific Officer and Vice President .
  Posted 10/21/09 at 11:56pm

Videos

Screenshots

edit

Sources

1. GlycoMimetics lands $38M round to fund new trials (fiercebiotech.com) [edit]